Paragon Bioservices Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Paragon Bioservices's estimated annual revenue is currently $12.6M per year.(i)
  • Paragon Bioservices received $5.0M in venture funding in August 2018.
  • Paragon Bioservices's estimated revenue per employee is $155,000
  • Paragon Bioservices's total funding is $20M.

Employee Data

  • Paragon Bioservices has 81 Employees.(i)
  • Paragon Bioservices grew their employee count by -13% last year.

Paragon Bioservices's People

CFO Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Paragon Bioservices?

Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon's aim is to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Paragon Bioservices News

2022-04-17 - Bioservices Market Size 2022 : COVID-19 Impact on Industry ...

The growth of the Bioservices market was mainly driven by the ... Inc, Ology Bioservices, Inc., Paragon Gene Therapy, Park Bioservices,...

2022-04-06 - Catalent injecting $160m into UK failed vaccine plant ...

... Maryland (added through the 2019 acquisition of Paragon Bioservices), ploughed $100 million into its Anagni, Italy fill-finish facility...

2022-04-06 - Stem Cell Services Market Key Trends And Opportunity Areas ...

Paragon Bioservices, APEX Biologix, VcanBio, Cryo-cell, Crioestaminal, LifeCell, ViaCord, Pepro Tech, Health Baby. Photo of Carl Allison Carl...

2019-09-08 - Catalent's legacy business outshined by acquisitions

By April of 2019, Catalent had agreed to a $1.2 billion acquisition of gene therapy developer Paragon Bioservices. And most recently, the ...

2019-09-07 - Viral vector and plasmid market set for rapid growth

Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Paragon Bioservices Funding

DateAmountRoundLead InvestorsReference
2014-10-29$13.0MUndisclosedNewSpring CapitalArticle